Hepatitis C Therapies Perform Well in Challenging Patients

Medscape Coverage from
Digestive Disease Week (DDW) 2017

Hepatitis C Therapies Perform Well in Challenging Patients
William F. Balistreri, MD

At this year's Digestive Disease Week, several studies looked into the nuances of treating hepatitis C virus (HCV)infection. Of particular interest were new data regarding difficult-to-treat groups and the validation of shorter, simpler regimens

Glecaprevir and PibrentasvirIn several phase 2 and 3 clinical trials, patients who received the pangenotypic direct-acting antivirals (DAAs) glecaprevir (GLE) and pibrentasvir (PIB) achieved sustained virologic response (SVR) rates of 92%-100% across all six major HCV genotypes...

Sofosbuvir/Velpatasvir/Voxilaprevir
A pangenotypic combination of sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX) was designed to inhibit three distinct HCV targets: the NS5B polymerase, the NS5A protein, and NS3/4A protease, respectively.

Flamm and colleagues^[3] presented cumulative data from 1056 patients with and without compensated cirrhosis who were infected with HCV genotype 1-6 and treated with the once-daily fixed-dose combination tablet of SOF/VEL/VOX in phase 3 studies....

Continue reading....

Free registration required

Medscape - Early Look at Two New Hepatitis C Pangenotypic Therapies

Medscape Coverage from
Digestive Disease Week (DDW) 2017

COMMENTARY
Early Look at Two New Hepatitis C Pangenotypic Therapies
Digestive Disease Week (DDW) 2017
Nancy S. Reau, MD

Despite the incredible evolution in hepatitis C (HCV) therapeutics, much remains to be done to affect the incidence, prevalence, and morbidity caused by this silent but curable disease. Several presentations at the recent Digestive Disease Week (DDW) meeting offer new perspectives in screening, reinfection, and therapy.

Risk-based screening was the primary way to identify individuals with chronic HCV until 2012, when the Centers for Disease Control and Prevention released recommendations to screen Americans born between 1945 and 1965, the birth cohort with the highest prevalence of chronic HCV and the most chronically infected with advanced fibrosis.
Continue reading.....

Healio Highlights from DDW - New data on liver disease diagnosis and treatment

Digestive Disease Week

May 6, 2017 - May 9, 2017

Healio brings you the highlights from Digestive Disease Week. Refer back to this page often for the latest news from DDW, perspectives and interviews with leading researchers and clinicians, and to review archives of past meetings.

Hepatology highlights from DDW include microbiome, LT, HBV
May 26, 2017
Among the presentations at this year’s Digestive Disease Week, physician experts and clinical professionals discussed new data on liver disease diagnosis and treatment, including topics such as gut microbiota, liver transplantation, fatty liver disease and viral hepatitis, as well as advances in the world of telemedicine and unique approaches in patient management.

Continue reading....